Skip to main content

Table 3 Independent risk factors for RFS and OS verified by univariate and multivariate analyses

From: Novel postoperative nomograms for predicting individual prognoses of hepatitis B-related hepatocellular carcinoma with cirrhosis

Clinical parameters

RFS

OS

HR (95% CI)

P-value

HR (95% CI)

P-value

Univariate analysis

SEX (male/female)

0.894 (0.596–1.210)

0.365

0.816 (0.537–1.238)

0.338

Age (≥ 60/< 60 years)

0.797 (0.600–1.06)

0.118

0.844 (0.608–1.170)

0.308

HBV-DNA (≥ 103/< 103 copies/mL)

1.433 (1.112–1.845)

0.005

1.566 (1.159–2.117)

0.004

HBeAg (positive/negative)

1.397 (1.067–1.830)

0.015

1.487 (1.094–2.021)

0.011

AFP (≤ 20/20–400/≥ 400 ng/mL)

1.801 (1.427–2.273)

< 0.001

1.912 (1.463–2.497)

< 0.001

WBC (≥ 4/< 4 × 109/L)

1.353 (0.957–1.913)

0.087

1.340 (0.900–1.995)

0.149

NEU (≥ 3.56/< 3.56 × 109/L)

1.310 (1.033–1.662)

0.026

1.529 (1.165–2.007)

0.002

LYM (≥ 1.1/< 1.1 × 109/L)

1.331 (1.005–1.763)

0.046

1.430 (1.027–1.992)

0.034

PLT (≥ 100/< 100 × 109/L)

1.205 (0.949–1.530)

0.126

1.424 (1.075–1.886)

0.014

PT (≥ 12.8/< 12.8 s)

0.953 (0.720–1.260)

0.735

0.929 (0.673–1.283)

0.656

INR (≥ 1.15/< 1.15)

0.897 (0.688–1.169)

0.421

0.923 (0.678–1.257)

0.611

Fib (≥ 2/< 2 g/L)

1.279 (0.930–1.761)

0.131

1.336 (0.904–1.997)

0.147

TB (≥ 28/< 28 μmol/L)

0.740 (0.447–1.226)

0.243

0.690 (0.376–1.265)

0.23

ALT (≥ 50/< 50 IU/L)

1.154 (0.912–1.458)

0.233

1.106 (0.843–1.452)

0.467

AST (≥ 40/< 40 IU/L)

1.255 (0.995–1.583)

0.055

1.391 (1.061–1.823)

0.017

ALB (≥ 40/< 40 g/L)

0.899 (0.708–1.141)

0.382

0.781 (0.594–1.026)

0.075

GGT (≥ 60/< 60 IU/L)

1.540 (1.220–1.943)

< 0.001

2.027 (1.539–2.669)

< 0.001

Child–pugh (A/B)

1.489 (0.663–3.344)

0.335

0.978 (0.367–2.655)

0.979

Tumor diameter

1.734 (1.370–2.195)

< 0.001

1.960 (1.487–2.583)

< 0.001

Tumor number (multiple/solitary)

1.543 (1.157–2.057)

0.003

1.217 (0.863–1.716)

0.263

Differentiation (III + IV/I + II)

1.300 (1.035–1.634)

0.024

1.653 (1.269–2.152)

< 0.001

MVI (present/negative)

2.130 (1.689–2.687)

< 0.001

2.529 (1.934–3.307)

< 0.001

Satellite (present/negative)

1.906 (1.396–2.603)

< 0.001

1.743 (1.217–2.496)

0.002

Anatomic hepatectomy (yes/no)

1.214 (0.961–1.534)

0.103

1.432 (1.095–1.873)

0.009

Blood loss (≥ 400/< 400 mL)

2.846 (0.860–9.415)

0.087

3.861 (0.902–16.529)

0.069

Transfusion (yes/no)

1.655 (0.819–3.346)

0.16

1.351 (0.600–3.043)

0.468

Multivariate analysis

HBeAg

1.423 (1.085–1.865)

0.011

1.528 (1.117–2.090)

0.008

AFP

1.546 (1.209–1.975)

0.001

1.417 (1.067–1.882)

0.016

Tumor diameter

1.038 (1.002–1.075)

0.041

1.054 (1.012–1.098)

0.012

MVI

1.906 (1.490–2.438)

< 0.001

2.009 (1.507–2.677)

< 0.001

Satellite lesion

1.791 (1.307–2.452)

< 0.001

1.458 (1.015–2.093)

0.041

GGT

ND

ND

1.388 (1.025–1.879)

0.034

Differentiation

ND

ND

1.375 (1.044–1.810)

0.012

  1. Bold numbers indicate statistical significance
  2. RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; HBV-DNA, hepatitis B virus deoxyribonucleic acid; HBeAg, hepatitis B e antigen; AFP, alpha-fetoprotein; WBC, white blood cell; NEU, neutrophil; LYM, lymphocyte; PLT, platelet; PT, prothrombin time; s, second; INR, international normalized ratio; Fib, fibrinogen; TBIL, total bilirubin; ALT, alanine transaminase; AST, aspartate aminotransferase; ALB, albumin; GGT, gamma-glutamyl transpeptidase; SD, standard deviation; MVI, microvascular invasion; ND, no data
Back to article page

BMC Surgery

ISSN: 1471-2482

Contact us